erlotinib hydrochloride has been researched along with bay 65-1942 in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (bay 65-1942) | Trials (bay 65-1942) | Recent Studies (post-2010) (bay 65-1942) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5 | 0 | 3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, EY; Cullen, KJ; Dan, H; Lapidus, RG; Li, Z; Liao, J; Liu, X; Yang, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and bay 65-1942
| Article | Year |
|---|---|
Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Mice; NF-kappa B; Oxazines; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2019 |